The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oyaLdL
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidiscip...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Abstract Soil conditioners can be used to compensate for the insufficient soil nutrition and organic matter (OM) of arable soils. However, ...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Ocular Vestibular Evoked Myogenic Potentials: Where Are We Now? Objective: Over the last decade, ocular vestibular evoked myogenic potential...
-
Abstract Objective To study the effects of Astragalus polysaccharide (APS), the primary effective component of the Chinese herb medicine A...
-
Publication date: Available online 6 January 2018 Source: Current Problems in Diagnostic Radiology Author(s): Mark D. Kovacs, Maximilian...
-
Background Chronic rhinosinusitis (CRS) is a commonly observed sequela after radiation therapy to the paranasal sinuses. The histopatholo...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου